Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : The *NEW* Frank Coluccio Technology Forum -- Ignore unavailable to you. Want to Upgrade?

To: Frank A. Coluccio who wrote (90)	6/7/2000 7:10:00 PM
From: Tarzan	Respond to of 46821

I found this press release on the Celsion web site about some Duke technology. It sounds promising. Any biochem nerds want to comment on this drug delivery approach? Celsion Corporation - News Release FOR IMMEDIATE RELEASE: Journal of Cancer Research Publishes Duke Study Which Describes a New Targeted Drug Delivery Platform - Celsion Corporation Has Exclusive License to the Duke Technology - Columbia, MD, March 2, 2000: Celsion Corporation today announced that the Journal of Cancer Research: Advances in Brief has published in its March 1 issue a Duke University study which describes a new formulation for a temperature triggered drug release system. This new drug delivery system uses temperature sensitive liposomes that are triggered to release drugs at temperatures that are clinically attainable using Celsion's focused heat thermotherapy equipment. The study was partially funded by Celsion, which owns all commercial rights to the system and to the enabling technologies. The Duke study describes a new lipid formulation containing doxorubicin that has been optimized for both a mild hyperthermic temperature threshold (39 degs C to 40 degs. C) and a rapid release of the drug at the tumor site. This new targeted drug delivery platform was found to be significantly more effective than a free drug or other standard liposome formulations in reducing tumor growth in a human squamous cell carcinoma xenograft line (FaDu) in mice. The Duke system produced 11 out of 11 complete regressions lasting 60 days post treatment, at which point the experiment ended. Please refer to dukenews.duke.edu for details. Celsion plans to develop and commercialize Duke's heat-sensitive liposomes to carry chemotherapeutic drugs to tumors. The goal of the program is to develop and commercialize a new generation of targeted "site specific" cancer drugs that would be many times more potent than current treatments, without significant side effects. According to Dr. Augustine Cheung, Celsion's Chairman and Chief Scientific Officer, "the combination of the new Duke technology and the focused heat technology exclusively licensed from the Massachusetts Institute of Technology (currently used in Celsion's Breast Cancer treatment system) may lead to a new targeted drug delivery technology platform which has potentially wide clinical applications for cancer and other diseases". Celsion is currently planning additional preclinical studies in order to make an IND (Investigative New Drug) application with the FDA before any human trials can be performed. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused heat technology delivered by patented microwave technology. Celsion has research or commercial associations with leading institutions such as Duke University, Harbor UCLA Medical Center, MIT, and Montifiore Medical Center. ###